| Active substance | Bimekizumab |
| Holder | UCB Biopharma SRL |
| Status | Running |
| Indication | Adults with moderate to severe Hidradenitis Suppurativa (HS) (acne inversa) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 29/10/2024 |